Hypercalcemia affects up to 30% of patients with cancer. 1 It has been seen in most cancers but is most common in patients with non-small cell lung cancer, breast cancer, multiple myeloma, head and ...

New research attempts to answer some of the mystery related to the causes and impact of hypercalcemia in patients with newly diagnosed multiple myeloma. Hypercalcemia is caused by many factors in ...

Hypercalcemia of malignancy (HCM) is the most common metabolic complication seen in patients with cancer, and is associated with a high degree of morbidity and mortality. It affects an estimated 2%–30 ...

September 19, 2007--Cinacalcet ( Sensipar, Amgen) may emerge as an important new therapeutic option for patients with inoperable parathyroid carcinoma, researchers report. According to the results of ...

Hypercalcemia is most common in those who have later-stage malignancies and predicts a poor prognosis for those with it. The most common causes include humoral hypercalcemia of malignancy mediated by ...

HYPERCALCEMIA occurs in a wide variety of diseases (for example, hyperparathyroidism, hypervitaminosis D, sarcoid, cancer, hyperthyroidism and poliomyelitis) 1 and is often responsible for many of the ...

Please provide your email address to receive an email when new articles are posted on . A new clinical practice guideline from the Endocrine Society recommends treatment with IV bisphosphonates or ...

Mutations in the calcium sensing receptor gene (CaSR) might be associated with high calcium levels leading to aggressive breast cancer disease in some women. High serum calcium has been found to be ...

Paraneoplastic syndromes are rarely seen in gynecological tumors especially in endometrial cancer. Early identification of paraneoplastic syndromes plays a significant role in the treatment and ...

Mutations in the CaSR gene may be at least partially responsible for high serum calcium levels in breast cancer patients which in turn lead to more aggressive disease and poorer prognosis, according ...